论文部分内容阅读
目的 探讨乳腺癌组织中基质金属蛋白酶 (MatrixMeralloproteinases,MMPS)和金属蛋白酶组织抑制物 (TissueInhibitorsofMeralloproteinases,TIMPS)基因表达与肿瘤发生、病理分级、转移及预后之间的关系。方法 采用免疫组化LSAB法对 5 0例具有完整临床资料的乳腺癌组织及 2 0例乳腺纤维腺瘤的组织标本分别进行MMP 2、MMP 9和TIMP 2标记检测。结果 5 0例乳腺癌组织中MMP 2、MMP 9和TIMP 2的表达分别为 74 % (37/ 5 0 )、6 5 % (31/ 5 0 )和 5 6 % (2 8/ 5 0 ) ,而在癌旁组织及良性纤维腺瘤增生的导管上皮中大部分不着色 ,少部分有微弱的着色 ,三者的表达与肿瘤的发生明显相关 ;MMP 2的高表达与肿瘤的病理分级、淋巴结的转移及临床预后复发均呈明显的正相关 (P <0 .0 5 ) ,TIMP 2的高表达与病理分级 ,淋巴结转移及预后复发呈明显的负相关 (P <0 .0 5 ) ,但MMP 9的表达却与临床因素无明显相关性。结论 乳腺癌组织中MMP 2高表达预示着病人预后更差 ,比MMP 9对乳癌患者转移及预后更具有判断价值 ,评价MMP 2和TIMP 2之间的平衡有利于早期了解预后 ,且比单独采用MMP 2指标更有利于了解癌肿的进展及预后。
Objective To investigate the relationship between the expression of matrix metalloproteinase (MMP) and tissue inhibitor of tissue metalloproteinase (TIMPS) in breast cancer and tumorigenesis, pathological grade, metastasis and prognosis. Methods The immunohistochemical LSAB method was used to detect the MMP 2, MMP 9 and TIMP 2 in 50 specimens of breast cancer and 20 specimens of breast fibroadenoma with complete clinical data. Results The expressions of MMP 2, MMP 9 and TIMP 2 in breast cancer tissues were 74% (37/50), 65% (31/50) and 56% (28/60) respectively, However, most of the ductal epithelia in the paracancerous tissues and benign fibroadenomas were not colored, and some were weakly colored. The expression of the three was significantly correlated with the tumorigenesis. The high expression of MMP-2 and the pathological grade of the tumor, (P <0.05). There was a significant negative correlation between the high expression of TIMP-2 and pathological grade, lymph node metastasis and prognosis (P <0.05) MMP 9 expression but no significant correlation with clinical factors. Conclusion The high expression of MMP-2 in breast cancer indicates that the prognosis of patients with breast cancer is worse than that of MMP-9, and it is more valuable to evaluate the metastasis and prognosis of patients with breast cancer. Evaluating the balance between MMP-2 and TIMP- MMP 2 index is more conducive to understanding the progress and prognosis of cancer.